1. Home
  2. KEQU vs CHRS Comparison

KEQU vs CHRS Comparison

Compare KEQU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kewaunee Scientific Corporation

KEQU

Kewaunee Scientific Corporation

HOLD

Current Price

$38.88

Market Cap

124.6M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.35

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEQU
CHRS
Founded
1906
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
124.6M
186.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
KEQU
CHRS
Price
$38.88
$1.35
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.02
AVG Volume (30 Days)
9.3K
961.1K
Earning Date
12-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.94
1.34
Revenue
$285,515,000.00
$277,728,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$67.29
P/E Ratio
$9.87
$1.01
Revenue Growth
43.02
152.07
52 Week Low
$30.33
$0.71
52 Week High
$71.33
$1.89

Technical Indicators

Market Signals
Indicator
KEQU
CHRS
Relative Strength Index (RSI) 46.44 51.35
Support Level $37.50 $1.31
Resistance Level $39.73 $1.41
Average True Range (ATR) 1.39 0.09
MACD 0.20 0.02
Stochastic Oscillator 46.77 68.93

Price Performance

Historical Comparison
KEQU
CHRS

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: